A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01421186 |
Recruitment Status :
Completed
First Posted : August 22, 2011
Results First Posted : October 28, 2021
Last Update Posted : November 16, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Multiple Myeloma | Drug: MOR03087 phase 1 dose escalation Drug: MOR03087 Drug: Dexamethasone Drug: Pomalidomide Drug: Lenalidomide | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 91 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1/2a, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of the Human Anti-CD 38 Antibody MOR03087 as Monotherapy and in Combination With Standard Therapy in Subjects With Relapsed/Refractory Multiple Myeloma |
Actual Study Start Date : | July 2011 |
Actual Primary Completion Date : | August 2020 |
Actual Study Completion Date : | August 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Phase 1 dose escalation
Part A: MOR03087 dose escalation; biweekly treatment Part B: MOR03087 dose escalation; weekly treatment Part C: MOR03087 dose escalation (weekly treatment) + dexamethasone Part D: MOR03087 weekly treatment in combination with pomalidomide + dexamethasone Part E: MOR03087 weekly treatment in combination with lenalidomide + dexamethasone For all parts, patients will be treated until disease progression (PD) or until a maximum of 3 years after first treatment. |
Drug: MOR03087 phase 1 dose escalation
Treatment cycles will be 28 days. Initial MOR03087 doses will be 0.01 mg/kg in part A, 4 mg/kg in parts B and C and 8 mg/kg in parts D and E; in all parts MOR03087 doses will be escalated to a maximum of 16 mg/kg. In part A, patients will receive a biweekly intravenous infusion of MOR03087 which will be administered on days 1 and 15 of the cycle. In parts B to E patients will receive a weekly intravenous infusion of MOR03087 which will be administered on days 1, 8, 15, and 22 of the cycle. In all parts a loading dose of MOR03087 will be additionally administered on day 4 of cycle 1. Drug: Dexamethasone Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (> 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4. Drug: Pomalidomide Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle. Drug: Lenalidomide Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle. |
Experimental: Phase 2a confirmatory cohorts
Confirmatory cohorts of MOR03087 monotherapy (plus or minus dexamethasone), in combination with pomalidomide plus dexamethasone, and in combination with lenalidomide plus dexamethasone. Following completion of Parts A, B, and C (dose escalation of MOR03087 biweekly and weekly schedules), the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen will be confirmed in a minimum of 6 subjects. Following completion of Parts D (dose escalation of MOR03087 in combination with pomalidomide + dexamethasone) and E (dose escalation of MOR03087 in combination with lenalidomide + dexamethasone), the MTD and/or recommended dose in each part will be confirmed in a minimum of 6 subjects. For all parts, patients will be treated until PD or until a maximum of 3 years after first treatment. |
Drug: MOR03087
MOR03087 will be administered according to the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E. Drug: Dexamethasone Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (> 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4. Drug: Pomalidomide Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle. Drug: Lenalidomide Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle. |
- Determination of Maximum Tolerated Dose and / or Recommended Dose and Dosing Regimen of MOR03087 [ Time Frame: First cycle of treatment ]
- as monotherapy
- in combination with dexamethasone
- in combination with pomalidomide + dexamethasone
- in combination with lenalidomide + dexamethasone
- Number of Participants Who Develop Anti-MOR03087 Antibodies [ Time Frame: during treatment period, maximum 3 years after 1st dose ]Number of participants who develop anti-MOR03087 antibodies, a measure of immunogenicity
- Overall Response Rate [ Time Frame: maximum 3 years after 1st dose ]number (#) of patients responding (# stringent complete response + # complete response + # very good partial response + # partial response)
- Time to Progression [ Time Frame: patients were observed for up to 36 months ]Time to Progression (Kaplan Meier estimate)
- Progression-free Survival [ Time Frame: patients were observed up to 36 months ]Progression-free survival (Kaplan Meier estimates)
- Duration of Response [ Time Frame: patients were observed up to 36 months ]Duration of response (Kaplan Meier estimates)
- Pharmacokinetics: Cmax - Maximum Observed Serum Concentration for MOR202 [ Time Frame: up to 7 days after last MOR202 dose ]PK analysis for MOR202 4, 8 and 16 mg/kg IV once weekly dose groups only, since serum concentrations of MOR202 were substantially affected by target mediated drug disposition effects for remaining dose groups
- Pharmacokinetics: AUC Cycle 1+2 - Area Under the Time/Concentration Curve for MOR202 [ Time Frame: 56 days ]PK analysis for MOR202 4, 8 and 16 mg/kg IV once weekly dose groups only, since serum concentrations of MOR202 were substantially affected by target mediated drug disposition effects for remaining dose groups

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female subjects 18 years and older
-
Relapsed or refractory multiple myeloma defined as:
Parts A, B and C:
(i) Failure of at least 2 previous therapies which must have included an immunomodulatory agent and a proteasome inhibitor (either together or part of different therapies) (ii) All subjects must have documented progression during or after their last prior therapy for multiple myeloma
Part D:
(i) At least 2 previous therapies including lenalidomide and a proteasome inhibitor (ii) All subjects must have documented progression during or within 60 days after their last prior therapy for multiple myeloma
Part E:
(i) Received at least one previous therapy (ii) All subjects must have documented progression during or after their last prior therapy for multiple myeloma
- Presence of serum M-protein ≥ 0.5 g per 100 mL (≥ 5 g/L) and / or urine M-protein ≥ 200 mg per 24-hour period
- Absolute neutrophil count (ANC) ≥ 1,000 / mm3
- Haemoglobin ≥ 8 g/dL
- Ability to comply with all study related procedures, medication use and evaluations
Exclusion Criteria:
- Primary refractory multiple myeloma
- History of significant cerebrovascular disease or sensory or motor neuropathy of toxicity grade 3 or higher
- Treatment with systemic investigational agent within 28 days prior to first study treatment
- Solitary plasmacytoma or plasma cell leukaemia
- Previous allogenic stem cell transplant (SCT)
- Prior therapy with other monoclonal antibodies targeting the CD38 antigen or prior therapy with other IgG monoclonal antibodies within 3 months prior to first study treatment, or IgM monoclonal antibodies within 1 month prior to first study treatment
- Active systemic infection
- Systemic disease preventing study treatment
- Multiple myeloma with central nervous system (CNS) involvement
- Previous treatment with cytotoxic chemotherapy or large field radiotherapy or other myeloma specific therapy within 28 days prior to first study treatment (radiation to a single site as concurrent therapy is allowed)
- Significant uncontrolled cardiovascular disease or cardiac insufficiency (New York Heart Association [NYHA] classes III, IV)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01421186
Austria | |
AKH (Allgemeines Krankenhaus der Stadt Wien), Abteilung für Klinische Onkologie, Universitätsklinik für Innere Medizin I | |
Vienna, Austria, 1090 | |
Germany | |
Charité - Universitätsmedizin Berlin, CBF: Campus Benjamin Franklin, CC 14: Tumormedizin, Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie | |
Berlin, Germany, 12200 | |
Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus | |
Dresden, Germany, 01307 | |
Medizinische Klinik 5 - Hämatologie und Internist. Onkologie, Universitätsklinikum Erlangen | |
Erlangen, Germany, 91054 | |
Medizinische Universitätsklinik, Abt. Innere Medizin I | |
Freiburg, Germany, 79106 | |
Universitäsklinikum Heidelberg, Klin.-Pharmakologisches Studienzentrum | |
Heidelberg, Germany, 69120 | |
Sektion für Stammzell- und Immuntherapie, II. Medizinischen Klinik, | |
Kiel, Germany, 24105 | |
Klinikum rechts der Isar/ Studien / III. Med. Klinik | |
Munich, Germany, 81675 | |
Medizinische Klinik II, Abt. Hämatologie, Onkologie, | |
Tübingen, Germany, 7206 | |
Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Studienambulanz für Hämatologie/Onkologie und Infektiologie | |
Würzburg, Germany, 97080 |
Documents provided by MorphoSys AG:
Responsible Party: | MorphoSys AG |
ClinicalTrials.gov Identifier: | NCT01421186 |
Other Study ID Numbers: |
MOR202C101 DRKS00003145 ( Registry Identifier: German Clinical Trail Register ) |
First Posted: | August 22, 2011 Key Record Dates |
Results First Posted: | October 28, 2021 |
Last Update Posted: | November 16, 2021 |
Last Verified: | July 2021 |
Multiple Myeloma MOR03087 (MOR202) Lenalidomide Pomalidomide CD38 |
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases Dexamethasone |
Lenalidomide Pomalidomide Felzartamab Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Immunologic Factors |